Safety Study of ADV-specific T-cells in Paediatric Patients Post Allo-HSCT

Summary

Human Adenovirus-specific T-cells can persist and augment impaired adenovirus immune response post allogeneic haematopoietic stem cell transplant, and reduce the requirement for antiviral therapy without toxicity or increasing the occurrence of Graft Versus Host Disease. This is a Phase I/IIa open-label safety study, assessing the effects of administering adenovirus-specific T-cells (Cytovir ADV) to paediatric patients post haematopoietic stem cell transplant.

Timeline

Start

2012-12

Primary completion

2016-12-31

Completion

2016-12-31

Drugs

Indications